Results 151 to 160 of about 54,075 (219)

Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2-positive metastatic colorectal cancer. [PDF]

J Comp Eff Res
Watkins C, Simon C, Martin P, Leadley R, Redhead G, Neuberger E, Bartley K.   +6 more
europepmc   +1 more source

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

BMJ
Ma F, Yan M, Li W, Ouyang Q, Tong Z, Teng Y, Wang Y, Wang S, Geng C, Luo T, Zhong J, Zhang Q, Liu Q, Zeng X, Sun T, Mo Q, Zhou S, Li P, Cheng J, Wang X, Nie J, Yang J, Wu X, Wang X, Li H, Yao G, Fan Y, Lin J, Zhu X, Xu B.   +29 more
europepmc   +1 more source

Trastuzumab Deruxtecan-Induced Pneumonitis: Case Series. [PDF]

Clin Case Rep
Alhuthali A, Alqurashi B, Banoun Y, Almuylibi Z, Sait H, Al-Sobhi B, Alnuhait M.   +6 more
europepmc   +1 more source

The Conjugation of Antibodies to Heat Shock Protein 70 Activates Immune Responses Against Tumor Cells. [PDF]

Immunotargets Ther
Khosravi M, Rajaei A, Mohammadian B, Seyfi Abad Shapouri M.   +3 more
europepmc   +1 more source

Characterization of HER2-Positive Murine Breast Cancer Models for Investigating HER2-Targeted Therapy and Immunotherapy. [PDF]

Cancers (Basel)
Lu Y, Lee BP, Eli AV, Lynch SE, Faisal ARM, Moye J, Sorace AG.   +6 more
europepmc   +1 more source

Real-World Safety and Efficacy of Biosimilar Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer: A Prospective Single-Institution Study From India. [PDF]

Int J Breast Cancer
Gandrala D, Rajappa SJ, Mallavarapu K, Santa A, Pavan Kumar B, Pinninti R, Ladda PS, Pathi N, Kandem S, Tewani RK, Thummar V, Mehta P.   +11 more
europepmc   +1 more source

Sympathetic Neural Overactivation, Vascular Dysfunction, and Exercise Intolerance in Long-Term Survivors of Breast Cancer Treated With Doxorubicin and Trastuzumab-Based Chemotherapy. [PDF]

J Am Heart Assoc
Izaias JE, Sales AO, Ono BE, Rodrigues TS, Silva GMPS, Pentagna PS, Albuquerque ALP, Folchini FN, Colombo FMC, Irigoyen MCC, Rodrigues AG, Negrão CE, Testa L, Rocha NG, Rocha HNM, Texeira GF, Nóbrega ACLD, Miyaguti NAS, Silva AAR, Porcari AM, Nascimento-Filho AV, De Angelis K, Craighead DH, Clayton ZS, Ludwig KR, Rossman MJ, Seals DR, Moll-Bernardes R, Sales ARK.   +28 more
europepmc   +1 more source

Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG). [PDF]

Cancers (Basel)
Dursun B, Yaslıkaya Ş, Sekmek S, Önder T, Yıldırım HÇ, Acar Ö, Sever N, Gökçek S, Ön S, Aslan F, Keskin GS, İşleyen ZS, Savaş G, Kalender ME, Paydaş S, Bal Ö, Arslan ÜY, Şahbazlar M, Çakar B, Türk HM, Akbulut H.   +20 more
europepmc   +1 more source

Selective fluorination of Fc glycans enhances antibody-mediated effector functions. [PDF]

Proc Natl Acad Sci U S A
Wang X, Gomozkova M, Li S, Banerjee B, Zong G, Missiakas D, Wang LX.   +6 more
europepmc   +1 more source

A prospective, multicenter, observational study of trastuzumab deruxtecan in elderly patients with HER2-positive gastric cancer: EN-COURAGE. [PDF]

ESMO Gastrointest Oncol
Narita Y, Kawabata R, Ando T, Arigami T, Kawakami H, Makiyama A, Uozumi R, Fukuda Y, Muro K.   +8 more
europepmc   +1 more source